AU · rank #5 · 2026-09-04
RCEL
NASDAQ · $338M (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 2.685 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.25 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 2 |
| Insider signal (90d) $41,700 across 1 unique buyers. | 2.409 |
| Analyst upside Consensus target $12.48 | +14.0% |
| Momentum acceleration 3-month minus 12-month momentum. | +122.97% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.50 |
| Gross margin TTM | +81.6% |
| 52w high | $11.20 |
| Market cap (USD) | $338M |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
AVITA Medical is a therapeutic acute wound-care company commercializing the RECELL platform for autologous skin cell-based regeneration to treat burns and wounds [RECENT_DEVELOPMENTS, BUSINESS_STATUS].
Rationale
The quant model's strong revision signals, including four target raises and 100% revision agreement, are validated by AVITA's Q2 2026 earnings beat and upwardly revised full-year revenue guidance to $86–$89 million [RECENT_DEVELOPMENTS].
Material risks
- 1High dilution and funding risk as the company's $11.1 million in cash and cash equivalents is insufficient relative to its $18.3 million net loss for the first half of 2026, necessitating continuous access to external capital [FINANCIAL_NOTES, TOP_RISKS].
- 2Concentrated commercial exposure to specialized burn and trauma centers with no long-term contracted backlog leaves revenue visibility entirely dependent on volatile procedure volumes [COMPETITIVE_POSITION, TOP_RISKS].
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.